GlassScriptPhysician profile
Santhosh K Cheela
NPI 1730169632
$4,663.60
in general payments reported to CMS, 2019-2025
17 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $241 · 2021: $707 · 2022: $787 · 2023: $756 · 2024: $798 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.45 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,416.88 | 2019-2024 | Rinvoq, Creon, Mavyret |
| Phathom Pharmaceuticals, INC. | $587.92 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $433.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $380.46 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.38 | 2019-2024 | Xifaxan, Plenvu |
| Novo Nordisk INC | $139.26 | 2022-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $119.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $108.83 | 2021 | |
| Genzyme Corporation | $80.65 | 2023-2025 | |
| Lilly USA, LLC | $58.94 | 2025 | Omvoh |
| Celgene Corporation | $53.22 | 2022-2023 | Zeposia |
| Pfizer INC. | $37.72 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.19 | 2024 | |
| Evoke Pharma, INC. | $15.48 | 2023 | Gimoti |
| Janssen Biotech, INC. | $14.34 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $13.90 | 2022 | |
| Redhill Biopharma INC. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santhosh Cheela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.